C
1.13
-0.02 (-2.17%)
| Penutupan Terdahulu | 1.15 |
| Jumlah Dagangan | 7,674 |
| Harga / Buku (P/B) | 0.340 |
| Julat 52 Minggu |
| EPS Cair (TTM) | -18.90 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 4.92% |
| Nisbah Semasa (MRQ) | 2.47 |
| Aliran Tunai Operasi (OCF TTM) | -43.60 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -46.50 M |
| Pulangan Atas Aset (ROA TTM) | -97.91% |
| Pulangan Atas Ekuiti (ROE TTM) | -208.72% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | Cellectar Biosciences, Inc. | Bercampur | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | 0.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 3.0 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | -0.5 |
| Penilaian Relatif | NA |
| Kesihatan Kewangan | 0.0 |
| Persekitaran Makro | -1.3 |
| AI Insight | NA |
| AI Technical | NA |
| Purata | 0.67 |
|
Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage a proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and safety as a result of fewer off-target effects. It has one operating and reportable segment focused on utilizing its PDC platform to develop drugs for the treatment of cancer. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 2.15% |
| % Dimiliki oleh Institusi | 6.91% |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |